Neuronetics, Inc. (STIM)
NASDAQ: STIM · Real-Time Price · USD
4.430
+0.040 (0.91%)
At close: Aug 1, 2025, 4:00 PM
4.420
-0.010 (-0.23%)
After-hours: Aug 1, 2025, 6:04 PM EDT
Chimerix Revenue
Neuronetics had revenue of $31.98M in the quarter ending March 31, 2025, with 83.59% growth. This brings the company's revenue in the last twelve months to $89.45M, up 22.16% year-over-year. In the year 2024, Neuronetics had annual revenue of $74.89M with 4.96% growth.
Revenue (ttm)
$89.45M
Revenue Growth
+22.16%
P/S Ratio
1.96
Revenue / Employee
$124,927
Employees
716
Market Cap
292.22M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 74.89M | 3.54M | 4.96% |
Dec 31, 2023 | 71.35M | 6.14M | 9.42% |
Dec 31, 2022 | 65.21M | 9.89M | 17.89% |
Dec 31, 2021 | 55.31M | 6.07M | 12.32% |
Dec 31, 2020 | 49.24M | -13.41M | -21.41% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
STIM News
- 3 days ago - NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents - GlobeNewsWire
- 18 days ago - Neuronetics Appoints New Chief Financial Officer - GlobeNewsWire
- 6 weeks ago - Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook's Personalized Care Trial Program - GlobeNewsWire
- 2 months ago - Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes - GlobeNewsWire
- 3 months ago - Neuronetics, Inc. (STIM) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Neuronetics Reports First Quarter 2025 Financial and Operating Results - GlobeNewsWire
- 4 months ago - Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression - GlobeNewsWire